September 26, 2018 / 3:46 PM / 19 days ago

Indivior sharply lowers revenue outlook for opioid addiction drug Sublocade

Sept 26 (Reuters) - Indivior Plc revised its full-year earnings guidance as it sharply lowered its revenue expectation for opioid addiction drug Sublocade on Wednesday.

The embattled British drugmaker said it now expects to post net revenue between $990 million and $1.02 billion and expects Sublocade to generate between $8 to $10 million of revenue in the full year 2018, lower than the $25 to $50 million it had earlier estimated.

Reporting by Sangameswaran S in Bengaluru; Editing by Elaine Hardcastle

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below